ARTICLE | Clinical News
Provenge: Phase III amended
September 19, 2005 7:00 AM UTC
DNDN amended the SPA for the ongoing Phase III D9902B trial. The trial, which was measuring TTP in men with Gleason scores <=7, will be opened to men with all Gleason scores and will have survival as ...